ES2745532T3 - Sobetirome en el tratamiento de enfermedades de mielinización - Google Patents

Sobetirome en el tratamiento de enfermedades de mielinización Download PDF

Info

Publication number
ES2745532T3
ES2745532T3 ES14791718T ES14791718T ES2745532T3 ES 2745532 T3 ES2745532 T3 ES 2745532T3 ES 14791718 T ES14791718 T ES 14791718T ES 14791718 T ES14791718 T ES 14791718T ES 2745532 T3 ES2745532 T3 ES 2745532T3
Authority
ES
Spain
Prior art keywords
sobetirome
disease
pharmaceutically acceptable
acceptable salt
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14791718T
Other languages
English (en)
Spanish (es)
Inventor
Meredith Hartley
Andrew Placzek
Marco Righi
Dennis Bourdette
Gail Marracci
Priya Chaudhary
Thomas S Scanlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
United States Department of Veterans Affairs
Original Assignee
Oregon Health & Science University
United States Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University, United States Department of Veterans Affairs filed Critical Oregon Health & Science University
Application granted granted Critical
Publication of ES2745532T3 publication Critical patent/ES2745532T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES14791718T 2013-05-03 2014-02-05 Sobetirome en el tratamiento de enfermedades de mielinización Active ES2745532T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
ES2745532T3 true ES2745532T3 (es) 2020-03-02

Family

ID=51843844

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14791718T Active ES2745532T3 (es) 2013-05-03 2014-02-05 Sobetirome en el tratamiento de enfermedades de mielinización

Country Status (12)

Country Link
US (3) US10226438B2 (enExample)
EP (1) EP2991670B8 (enExample)
JP (4) JP2016517883A (enExample)
CN (1) CN105431163A (enExample)
AU (1) AU2014260468A1 (enExample)
BR (1) BR112015027682A2 (enExample)
CA (1) CA2911309A1 (enExample)
ES (1) ES2745532T3 (enExample)
MX (2) MX379043B (enExample)
RU (1) RU2015151216A (enExample)
SG (2) SG10201709090UA (enExample)
WO (2) WO2014178892A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN108430514B (zh) * 2015-10-29 2023-11-03 约翰霍普金斯大学 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
CN109641003A (zh) * 2016-04-22 2019-04-16 维京治疗股份有限公司 甲状腺β-激动剂的应用
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
MX382313B (es) 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
EP3644983B1 (en) 2017-06-29 2023-10-25 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
US11633433B2 (en) 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
WO2019094952A1 (en) 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
AU2022271304A1 (en) 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2000502086A (ja) 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
JP2002519340A (ja) 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
AU2004273986B2 (en) * 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
CA2583410A1 (en) * 2004-09-15 2006-03-23 Albany College Of Pharmacy Thyroid hormone analogs for promoting angiogenesis
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
NZ576424A (en) 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8623861B2 (en) 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
TW201221505A (en) * 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
WO2014063720A1 (en) * 2012-10-25 2014-05-01 Renault Trucks Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Also Published As

Publication number Publication date
WO2014178892A1 (en) 2014-11-06
MX379043B (es) 2025-03-10
JP6360552B6 (ja) 2018-08-15
JP6360552B2 (ja) 2018-07-18
SG10201709090UA (en) 2017-12-28
EP2991670B8 (en) 2019-09-11
EP2991670A1 (en) 2016-03-09
WO2014178931A8 (en) 2015-11-26
MX2021000538A (es) 2021-04-28
WO2014178892A8 (en) 2015-12-17
BR112015027682A2 (pt) 2017-08-29
SG11201509012QA (en) 2015-11-27
AU2014260468A1 (en) 2015-11-19
JP2016517883A (ja) 2016-06-20
CN105431163A (zh) 2016-03-23
US11510887B2 (en) 2022-11-29
US20160081955A1 (en) 2016-03-24
JP2018141024A (ja) 2018-09-13
US20200405669A1 (en) 2020-12-31
WO2014178931A1 (en) 2014-11-06
RU2015151216A (ru) 2017-06-08
US10226438B2 (en) 2019-03-12
CA2911309A1 (en) 2014-11-06
MX2015015228A (es) 2016-10-03
JP2018162321A (ja) 2018-10-18
EP2991670A4 (en) 2017-01-18
HK1222552A1 (en) 2017-07-07
EP2991670B1 (en) 2019-07-03
JP2016517884A (ja) 2016-06-20
US20190175531A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
US11510887B2 (en) Sobetirome in the treatment of myelination diseases
US20240024271A1 (en) Methods and Compositions for Preventing and Treating Auditory Dysfunctions
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
CA3226805A1 (en) Paraxanthine-based caffeine substitute compositions and method of use thereof in slow caffeine metabolizers
ES2236551T3 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
ES2385702T3 (es) Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
CN106456606A (zh) 吲哚基及吲哚啉基异羟肟酸于治疗神经退化病症或认知缺乏的用途
WO2023101866A1 (en) Fenfluramine for treatment of conditions associated with spreading depolarization
WO2015063239A1 (en) Nasal compositions stimulating ciliary activity
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
US20210369720A1 (en) Synergistic composition having neuroprotective properties and methods of use thereof
KR101896441B1 (ko) 국소투여형의 연하장애 개선용 의약품
CN104411308A (zh) 通过给予某些合成化合物治疗阿尔茨海默病的方法
HK1222552B (en) Sobetirome in the treatment of myelination diseases
RU2345778C1 (ru) Способ лечения расстройств эрекции у мужчин
GB2547241A (en) Anti-inflammatory formulation
RU2345763C1 (ru) Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин
HK40119437A (en) Method for preventing or treating hearing loss
ES2575736T3 (es) Composición de extractos ricos en elagitaninos para el bienestar sexual
ES2946699A1 (es) Extracto de cerebro de cerdo y su uso en el tratamiento de enfermedades neurodegenerativas
ITUB20153895A1 (it) Associazione di curcumina, arginina e vitamina d
KR20160018806A (ko) 연하장애 개선용 의약품
Fedorov et al. COMPARATIVE ANALYSIS OF CLINICAL AND IMMUNOLOGICAL INDICATORS OF PHARMACOREISTITENIC PATIENTS WITH SCHIZOPHRENIA COMBODY WITH TUBERCULOSIS OF LUNGS WHEN PURPOSE OF FLUANXOL AND CYCLOPHERON
CA2944750A1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci
JP2013237666A (ja) 過労又は慢性疲労に伴う疾患の治療及び／又は予防剤